Compare MXC & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXC | VNRX |
|---|---|---|
| Founded | 1972 | N/A |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Oil & Gas Production | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 24.5M |
| IPO Year | 1995 | 2012 |
| Metric | MXC | VNRX |
|---|---|---|
| Price | $8.65 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 11.6K | ★ 312.9K |
| Earning Date | 02-10-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | 30.65 | ★ 38.00 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,705,235.00 | $1,727,384.00 |
| Revenue This Year | N/A | $355.66 |
| Revenue Next Year | N/A | $849.08 |
| P/E Ratio | $28.43 | ★ N/A |
| Revenue Growth | 7.12 | ★ 40.04 |
| 52 Week Low | $7.80 | $0.13 |
| 52 Week High | $16.48 | $3.26 |
| Indicator | MXC | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 36.87 |
| Support Level | $8.57 | $0.22 |
| Resistance Level | $9.63 | $2.89 |
| Average True Range (ATR) | 0.38 | 0.24 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 21.74 | 5.79 |
Mexco Energy Corporation is an independent oil and gas company. It is engaged in the acquisition, exploration, development, and production of natural gas and crude oil properties located in the United States. The company carried out its operation in the Permian Basin of West Texas. It is focusing on two primary areas, the Delaware Basin located in the Western portion of the Permian Basin including Lea and Eddy Counties, New Mexico and Loving County, Texas, and the Midland Basin located in the Eastern portion of the Permian Basin including Reagan, Upton, Midland, Martin, Howard, and Glasscock Counties, Texas. The company generates revenue from Oil sales, Natural gas sales, oil and gas royalty interests.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.